+357 96 030922
info@marketpublishers.com

Global Breast Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030

https://marketpublishers.com/r/GDD89D96E0ADEN.html
Date: September 2025
Pages: 330
Price: US$ 3,000.00 (Single User License)
ID: GDD89D96E0ADEN

Abstracts

Research Methodology

Global Breast Cancer Antibody Drug Conjugates Market Opportunity: > US$ 20 Billion By 2030

Global & Regional Market Size Insight (Yearly & Quarterly): 2020 Till H1?2025

Approved Breast Cancer Antibody Drug Conjugates Sales Insight : 2020 Till 2025

Global Cancer Antibody Drug Conjugates Market Forecast: 2026 Till 2030

Approved Breast Cancer Antibody Drug Conjugates Patent, Dosage and Price Analysis

Breast Cancer Antibody Drug Conjugates In Clinical Trials: > 100 Drugs

Breast Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase

Cancer Antibody Drug Conjugates Development Platforms By Company

Need For Antibody Drug Conjugates In Breast Cancer Treatment & Why This Report

+357 96 030922
info@marketpublishers.com

Antibody drug conjugates (ADCs) are rapidly becoming an essential innovation in the battle against breast cancer, specifically in fulfilling the unmet needs of patients with HER2-positive and HER2-low tumors. These drugs leverage the precision targeting of monoclonal antibodies along with the potent cytotoxic effects of chemotherapeutic drugs to achieve more localized destruction of the tumor while avoiding systemic toxicity. The global market has identified this potential, with breast cancer ADCs sales exceeding US$ 7 Billion in 2024, and further expected to triple by 2030.

The purpose of this report is to provide an incisive, timely, and strategic insight into the developing landscape of breast cancer ADCs. As the space evolves from nascent research into broad clinical acceptance, stakeholders, ranging from pharmaceutical developers to investors, need current intelligence on clinical developments, trial design, platform technologies, and commercialization avenues. By boiling down sophisticated global data by geography, subtype, and trial phase, this report arms decision-makers with the insights needed to navigate and shape the direction of breast cancer treatment.

Clinical Trials Insight Included In Report

The report contains extensive analysis of ADC candidates for breast cancer, from early Phase 1 to late stage Phase 3 trials, including extensive data on already approved breast cancer ADCs These trials span across key geographies like the US, Europe, China, and Australia. Clinical data not only target the classic HER2-positive patients but also the emerging HER2-low patient population, a new area in breast cancer precision medicine. Report includes insight on more than 120 breast cancer antiboduies drug conjugates.

The most crucial variables examined are therapeutic strategy (monotherapy versus combination regimens), sponsorship of trials (academic centers versus industry), and molecular targets other than HER2, i.e., TROP2 and B7-H4. The key contenders in the late-stage pipeline are Enhertu, Trodelvy, Datroway, and new entrants such as DP303c, Izalontamab brengitecan, and JSKN003. Combination studies, such as sacituzumab govitecan with pembrolizumab or trastuzumab, are also investigated, providing solutions to mechanisms of resistance. Companion diagnostics, including Roche's TROP2 assay based on AI, are also included in trial designs to enable biomarker-based patient selection. Combined, all these insights chart the most productive and successful clinical activities globally.

Top Companies Working On R&D of Breast Cancer Antibody Drug Conjugates

A number of pharma titans and cutting-edge biotech players are defining the breast cancer ADC market. Daiichi Sankyo and AstraZeneca dominate with Enhertu, the category leader in global sales. Roche and Genentech remain active through Kadcyla and diagnostics. Seagen, having just been acquired by Pfizer, is adding pipeline depth, while ADC Therapeutics and Mersana Therapeutics are gaining traction with differentiated platforms.

Emerging companies such as RemeGen and Zydus Cadila are broadening the geographic reach, especially in Asia. Each company is developing new payloads, linkers, and antibody formats to decrease toxicity and enhance clinical efficacy. These are manifestations not only of innovation, but of intense competition that's driving global development and access.

Technology Platforms, Collaborations & Agreements

Technology platforms are the biggest differentiator in breast cancer ADCs. Companies are optimizing conjugation methods, linker chemistry, and payload delivery systems. For instance, bispecific ADCs (BsADCs), targeting two antigens at the same time, are being introduced as a next-generation answer for tumor heterogeneity. Part of the success of Enhertu lies in its high drug-to-antibody ratio and stable linker technology.

Collaborations are also driving expansion. Pfizer's acquisition of Seagen added propriety ADC platforms to its fold. Academic research institution-industry collaborations, like in the form of clinical trial partnerships,are speeding up candidate development. Licensing deals and local manufacturing support through CDMOs are also making access wider, particularly across emerging markets like India, China, and Latin America.

Report Indicating Future Direction Of Breast Cancer Antibody Drug Conjugates

This report predicts that breast cancer will continue to be the predominant indication for ADC innovation and commercialization. With additional candidates making their way into late-stage trials, and combination regimens demonstrating early efficacy, the future is directed toward more personalized and targeted therapy. Emerging innovations to watch are bispecific ADCs, increased biomarker testing, use in neoadjuvant/adjuvant treatment, and use in early-stage disease.

Regulatory momentum, investment capital, and scientific advancements are all coming

+357 96 030922
info@marketpublishers.com

together to pave the way for ADCs to be a cornerstone in the treatment of breast cancer. With an active pipeline, mounting international approvals, and growing indications, breast cancer ADCs can change the face of oncology care.

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

+357 96 030922
info@marketpublishers.com

Contents

1. INTRODUCTION TO BREAST CANCER ANTIBODY DRUG CONJUGATES

2. ANTIBODY DRUG CONJUGATES AS BREAST CANCER TARGETED THERAPY

2.1 Mechanism Of Antibody Drug Conjugates
2.2 Applications & Advantages In Breast Cancer
2.3 Comparison With Traditional Therapies
2.4 Breast Cancer Antibody Drug Conjugates Combination Therapies

3. GENERATIONS OF BREAST CANCER ANTIBODY DRUG CONJUGATES

3.1 Antibody Drug Conjugates - Evolution
3.2 Next Generation Antibody Drug Conjugates Prospects

4. COMMERCIALLY APPROVED BREAST CANCER ANTIBODY DRUG CONJUGATES BY BRAND NAME, COMPANY & INDICATION

5. GLOBAL BREAST CANCER ANTIBODY DRUG CONJUGATES MARKET OUTLOOK

5.1 Current Market Scenario
5.2 Global Breast Cancer Antibody Drug Conjugates Market Trends & Development
5.3 Future Growth Avenues

6. GLOBAL CANCER ANTIBODY DRUG CONJUGATES RESEARCH & MARKET TRENDS BY REGION

6.1 US
6.2 China
6.3 Europe
6.4 South Korea
6.5 Australia
6.6 Canada
6.7 Japan
6.8 UK
6.9 India
6.10 Latin America

+357 96 030922
info@marketpublishers.com

7. APPROVED BREAST CANCER ANTIBODY DRUG CONJUGATES - PATENT, DOSAGE & PRICE ANALYSIS

This Chapter Gives Insight On 7 Approved Breast Cancer Antibody Drug Conjugates
7.1 Kadcyla
  7.1.1 Overview, Availability & Patent Insight
  7.1.2 P ricing & Dosage Insight
...
7.7 Aidixi
  7.7.1 Overview & Availability Insight

8. APPROVED BREAST CANCER ANTIBODY DRUG CONJUGATES SALES INSIGHTS

8.1 Kadcyla
8.2 Enhertu
8.3 Trodelvy
8.4 Datroway

9. GLOBAL CANCER ANTIBODY DRUG CONJUGATES CLINICAL TRIALS OVERVIEW

9.1 By Phase
9.2 By Indication
9.3 By Company
9.4 By Country

10. GLOBAL CANCER ANTIBODY DRUG CONJUGATES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE

10.1 Research
10.2 Preclinical
10.3 Phase I
10.4 Phase I/II
10.5 Phase II
10.6 Phase II/III
10.7 Phase III
10.8 Preregistration

+357 96 030922
info@marketpublishers.com

10.9 Registered

11. MARKETED CANCER ANTIBODY DRUG CONJUGATES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE

12. CANCER ANTIBODY DRUG CONJUGATES DEVELOPMENT PLATFORMS BY COMPANY

13. GLOBAL CANCER ANTIBODY DRUG CONJUGATES MARKET OVERVIEW

13.1 Key Market Growth Drivers
13.2 Challenges For Market Growth

14. COMPETITIVE LANDSCAPE

14.1 ADC Therapeutics
14.2 AstraZeneca
14.3 Biocytogen
14.4 Biokin
14.5 Bristol Myers Squibb
14.6 Daiichi Sankyo
14.7 Duality Biologics
14.8 Eli Lilly
14.9 Gilead
14.10 Immunogen
14.11 Innovent Biologics
14.12 LigaChem Biosciences
14.13 Merck
14.14 Pfizer
14.15 Roche

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 2-1: Comparison Between Antibody Drug Conjugates & Traditional Cancer Therapies
Table 2-2: Breast Cancer ? Ongoing Antibody Drug Conjugate Combination Clinical Trials

Table 3-1: Breast Cancer ? Approved Second Generation Antibody Drug Conjugates
Table 3-2: Breast Cancer ? Approved Third Generation Antibody Drug Conjugates
Table 3-3: Fourth Generation Antibody Drug Conjugates - Examples

Table 4-1: Breast Cancer - Approved Antibody Drug Conjugates, September?2025

Table 5-1: Breast Cancer ? Approved Antibody Drug Conjugates

Table 6-1: US - Approved Breast Cancer Antibody Drug Conjugates, September?2025
Table 6-2: China - Approved Antibody Drug Conjugates, September?2025
Table 6-3: EU - Approved Cancer Antibody Drug Conjugates, September?2025
Table 6-4: Australia - Approved Cancer Antibody Drug Conjugates, September?2025
Table 6-5: Canada ? Approved Cancer Antibody Drug Conjugates, September?2025
Table 6-6: Japan ? Approved Cancer Antibody Drug Conjugates, September?2025
Table 6-7: UK - Approved Antibody Drug Conjugates, September?2025

Table 7-1: Datroway - Premedication & Concomitant Medications
Table 7-2: Datroway - Recommended Dosage Reductions for Adverse Reactions

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 2-1: Antibody Drug Conjugates ? General Working Mechanism
Figure 2-2: Advantages Of Antibody Drug Conjugates
Figure 2-3: Antibody Drug Conjugate Combinations In Studies

Figure 3-1: Cancer Antibody Drug Conjugates ? Opportunities For Next Generation Development

Figure 5-1: Global ? Breast Cancer Antibody Drug Conjugates Market (US$ Million), 2020-2025
Figure 5-2: Global ? Breast Cancer Antibody Drug Conjugate Sales By Drugs (US$ Million), H1?2025
Figure 5-3: Global ? Cancer Antibody Drug Conjugate Market Share By Drugs (%), H1?2025
Figure 5-4: Global ? Breast Cancer Antibody Drug Conjugate Market (US$ Million), Q1 & Q2?2025
Figure 5-5: Global ? Breast Cancer Antibody Drug Conjugate Sales By Drugs (US$ Million), 2024
Figure 5-6: Global ? Breast Cancer Antibody Drug Conjugate Market Share By Drugs (%), 2024
Figure 5-7: Global ? Breast Cancer Antibody Drug Conjugate Market (US$ Million), Q1 -Q4?2024
Figure 5-8: Global ? Breast Cancer Antibody Drug Conjugate Market By Drugs (US$ Million), 2023
Figure 5-9: Global ? Cancer Antibody Drug Conjugate Market Share By Drugs (%), 2023
Figure 5-10: D926QC00001 Phase 3 (NCT06112379) Study ? Initiation & Completion Year
Figure 5-11: TQB2102-III-01 Phase 3 (NCT06561607) Study ? Initiation & Completion Year
Figure 5-12: IZABRIGHT-Breast01 Phase 2/3 (NCT06926868) Study ? Initiation & Completion Year
Figure 5-13: STARt-002 Phase 1/2 (NCT06827613) Study ? Initiation & Completion Year
Figure 5-14: Global ? Breast Cancer Antibody Drug Conjugate Market Forecast (US$ Billion), 2026 ? 2030

Figure 6-1: India ? Branded v/s Biosimilar Trastuzumab Emtansine Price by Supply (US$), September?2025

Figure 7-1: US - Kadcyla FDA Approval Year By Indication
Figure 7-2: Kadcyla - Approval Year By Region
Figure 7-3: US - Kadcyla FDA Approval & Patent Expiration Year
Figure 7-4: Kadcyla ? Cost of Supply In US & Europe (US$), September?2025
Figure 7-5: Kadcyla ? Recommended Dose after 1st & 2nd Dose Reduction (mg/kg)
Figure 7-6: Enhertu - Approval Year By Region
Figure 7-7: US - Polivy FDA Approval Year by Indication
Figure 7-8: Enhertu ? FDA Orphan Drug Designation & Exclusivity Expiration Year
Figure 7-9: Enhertu ? Cost of 100 mg Supply In US & Europe (US$), September?2025
Figure 7-10: US - Trodelvy FDA Approval by Indication
Figure 7-11: Trodelvy - Approval Year By Region
Figure 7-12: Trodelvy - Patent Expiration By Region
Figure 7-13: Trodelvy - Cost of Supply In US & Europe (US$), September?2025
Figure 7-14: Ujvira ? Cost of 100 mg & 160 mg Supply in India (US$), September?2025
Figure 7-15: Datroway ? Cost of 100 mg Supply In US & Europe (US$), September?2025

Figure 8-1: Kadcyla - Global Sales (US$ Million), 2020-2025
Figure 8-2: Kadcyla - Global Quarterly Sales (US$ Million), Q1 & Q2?2025
Figure 8-3: Kadcyla - Global Sales By Region (%), H1?2025
Figure 8-4: Kadcyla - Global Quarterly Sales (US$ Million), Q1-Q4?2024
Figure 8-5: Kadcyla - Global Sales By Region (US$ Million), 2024
Figure 8-6: Kadcyla - Global Sales By Region (%), 2024
Figure 8-7: Kadcyla ? US Annual Sales (US$ Million), 2020-2025
Figure 8-8: Kadcyla ? US Quarterly Sales (US$ Million), Q1 & Q2?2025
Figure 8-9: Kadcyla ? US Quarterly Sales (US$ Million), Q1-Q4?2024
Figure 8-10: Kadcyla ? Europe Annual Sales (US$ Million), 2020-2025
Figure 8-11: Kadcyla - Europe Quarterly Sales (US$ Million), Q1?2025
Figure 8-12: Kadcyla - Europe Quarterly Sales (US$ Million), Q1-Q4?2024
Figure 8-13: Kadcyla - Japan Annual Sales (US$ Million), 2020-2025
Figure 8-14: Kadcyla - Japan Quarterly Sales (US$ Million), Q1 & Q2?2025
Figure 8-15: Kadcyla - Japan Quarterly Sales (US$ Million), Q1-Q4?2024
Figure 8-16: Kadcyla - ROW Annual Sales (US$ Million), 2020-2025
Figure 8-17: Kadcyla - ROW Quarterly Sales (US$ Million), Q1 & Q2?2025

+357 96 030922
info@marketpublishers.com

Figure 8-18: Kadcyla - ROW Quarterly Sales (US$ Million), Q1-Q4?2024
Figure 8-19: Enhertu - Global Annual Sales (US$ Million), 2020-2025
Figure 8-20: Enhertu - Global Quarterly Sales (US$ Million), Q1 & Q2?2025
Figure 8-21: Enhertu - Global Quarterly Sales (US$ Million), Q1-Q4?2024
Figure 8-22: Trodelvy - Global Annual Sales (US$ Million), 2020-2025
Figure 8-23: Trodelvy - Global Quarterly Sales (US$ Million), Q1 & Q2?2025
Figure 8-24: Trodelvy - Annual Sales By Region (US$ Million), 2025
Figure 8-25: Trodelvy - Annual Sales By Region (%), 2025
Figure 8-26: Trodelvy ? Global Quarterly Sales (US$ Million), Q1-Q4?2024
Figure 8-27: Trodelvy - Annual Sales By Region (US$ Million), 2024
Figure 8-28: Trodelvy - Annual Sales By Region (%), 2024
Figure 8-29: Trodelvy - US Annual Sales (US$ Million), 2020-2025
Figure 8-30: Trodelvy - US Quarterly Sales (US$ Million), Q1 & Q2?2025
Figure 8-31: Trodelvy - US Quarterly Sales (US$ Million), Q1-Q4?2024
Figure 8-32: Trodelvy - Europe Annual Sales (US$ Million), 2020-2025
Figure 8-33: Trodelvy ? Europe Quarterly Sales (US$ Million), Q1 & Q2?2025
Figure 8-34: Trodelvy - Europe Quarterly Sales (US$ Million), Q1-Q4?2024
Figure 8-35: Trodelvy - ROW Annual Sales (US$ Million), 2022-2025
Figure 8-36: Trodelvy ? ROW Quarterly Sales (US$ Million), Q1 & Q2?2025
Figure 8-37: Trodelvy - ROW Quarterly Sales (US$ Million), Q1-Q4?2024
Figure 8-38: Datroway - Global Annual Sales (US$ Million), 2025
Figure 8-39: Datroway - Global Quarterly Sales (US$ Million), Q1 & Q2?2025

Figure 9-1: Global ? Cancer Antibody Drug Conjugate In Clinical Trials By Phase, 2025 Till 2030
Figure 9-2: Global? Cancer Antibody Drug Conjugate In Clinical Trials By Indication, 2025 Till 2030
Figure 9-3: Global ? Cancer Antibody Drug Conjugate In Clinical Trials By Company, 2025 Till 2030
Figure 9-4: Global ? Cancer Antibody Drug Conjugate In Clinical Pipeline By Country, 2025 Till 2030

Figure 12-1: Proprietary ADC Technology ? Seagen
Figure 12-2: ALE.P02 & ALE.P03 ? Alentis Therapeutics
Figure 12-3: TRAAC - Tallac Therapeutics
Figure 12-4: ATAC - Heidelberg Pharma
Figure 12-5: Tub-tag? & P5 ? Tubulis

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Breast Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030

Product link: https://marketpublishers.com/r/GDD89D96E0ADEN.html

Price: US$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GDD89D96E0ADEN.html